The ESCMID Study Group for Mycobacterial Infections (ESGMYC) is dedicated to fighting mycobacterial infections, including tuberculosis, leprosy, and non-tuberculous mycobacterial infections. Aiming to improve their diagnosis, treatment, and prevention, ESGMYC is committed to:
ESGMYC LMIC Travel Grants
The ESCMID Study Group for Mycobacterial Infections (ESGMYC) is pleased to offer two travel grants (up 750 EUR each) to attend ESCMID Global 2025. Eligibility conditions are:
Selection will be done based on the above. Candidates should also submit a 1-page motivation letter and full CV. Selected participants will have to attend the ESGMYC meeting at ESCMID Global 2025 to present an proposal for research collaboration, or a research study or a webinar.
The deadline to apply is 28 February 2025.
Prosthetic Joint Infections Caused by Mycobacterium tuberculosis Complex-An ESGIAI-ESGMYC Multicenter, Retrospective Study and Literature Review.
Auñon A, Salar-Vidal L, Mahillo-Fernandez I, Almeida F, Pereira P, Lora-Tamayo J, Ferry T, Souèges S, Dinh A, Escudero R, Menéndez Fernández-Miranda C, Rico A, Rossi N, Esteban J. Microorganisms. 2024 Apr 24;12(5):849
Incidence and clinical significance of non-tuberculous mycobacteria among migrants in Denmark: A nationwide register-based cohort study from 1991 through 2021.
Dahl VN, Hermansen TS, Andersen AB, van Ingen J, Svensson E, Wejse CM, Lillebaek T; ESGITM and ESGMYC. Travel Med Infect Dis. 2024 Sep-Oct;61:102736
Impact of the COVID-19 pandemic on the real-world diagnostic infrastructure for tuberculosis-An ESGMYC collaborative study.
Paulowski L, Filip R, Jankovic Makek M, Guglielmetti L, Goletti D, van Ingen J, Kranzer K, Maurer FP; ESGMYC. PLoS One. 2024 Apr 16;19(4):e0291404.
Clinical standards for the management of adverse effects during treatment for TB.
Singh KP, Carvalho ACC, Centis R, D'Ambrosio L, Migliori GB, Mpagama SG, Nguyen BC, Aarnoutse RE, Aleska A, van Altena R, Bhavani PK, Bolhuis M, Borisov S, ‘t Boveneind-Vrubleuskaya N, Bruchfeld J, Caminero JA, Carvalho I, Cho JG, Davies-Forsman L, Dedicoat M, Dheda K, Dooley K, Furin J, Garcia-Garcia JM, Garcia-Prats A, Hesseling AC, Heysell SK, Hu Y, Kim HY, Manga S, Marais B, Margineanu I, Märtson AG, Munoz M Torrico, Nataprawira HM, Nuntes E, Ong CWM, Otto-Knapp R, Palmero DJ, Peloquin CA, Rendon A, Rossato Silva D, Ruslami R, Saktiawati AMI, Santoso P, Schaaf HS, Seaworth B, Simonsson U, Singla R, Skrahina A, Solovic I, Srivasta SK, Stocker SL, Sturkenboom MG, Svensson EM, Tadolini M, Thomas TA, Tiberi S, Trubiano J, Udwadia ZF, Verhage A, Vu DH, Akkerman OW, Alffenaar JWC, Denholm JT. Int J Tuberc Lung Dis. 2023;27(7):506–519.
Standards for clinical trials for treating TB.
du Cros P, Greig J, Alffenaar J, Cross GB, Cousins C, C Berry, Khan U, Phillips PPJ, Velásquez GE, Furin J, Spigelman M, Denholm J, Thi SS, Tiberi S, Huang GKL, Marks GB, Turkova A, Guglielmetti L, Chew KL, Nguyen HT, Ong CWM, Brigden G, Singh K, Motta I, Lange C, Seddon JA, Nyang’wa BT, Maug AKJ, Gler MT, Dooley KE, Quelapio M, Tsogt B, Menzies D, Cox V, Upton CM, Skrahina A, McKenna L, Horsburgh R, Marais BJ. Int J Tuberc Lung Dis. 2023;27(12):885–898.
Recent advances in the treatment of tuberculosis.
Motta I, Boeree M, Chesov D, Dheda K, Günther G, Horsburgh CR Jr, Kherabi Y, Lange C, Lienhardt C,McIlleron HM, Paton NI, Stagg HR, Thwaites G, Udwadia Z, Van Crevel R, Velásquez GE, Wilkinson RJ, Guglielmetti L; Study group on Mycobacteria (ESGMYC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Clin Microbiol Infect. 2023;22:S1198-743X(23)00339-7.
Towards clinical breakpoints for non-tuberculous mycobacteria – Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
Fröberg G, Maurer FP, Chryssanthou E, Fernström L, Benmansour H, Boarbi S, Mengshoel AT, Keller PM, Viveiros M, Machado D, Fitzgibbon MM, Mok S, Werngren J, Cirillo DM,Alcaide F, Hyyryläinen HL, Aubry A, Andres S, Nadarajan D, Svensson E, Turnidge J, Giske CG, Kahlmeter G, Cambau E, van Ingen J, Schön T; EUCAST AMST and ESGMYC study groups. Clin Microbiol Infect. 2023;29(6):758–764.
Joint ESGMYC and NTM-NET webinar: Critical review on recent drug resistant-TB trials and challenges related to implementation of new WHO recommendations
WORKSHOP INNOVATION IN TUBERCULOSIS 2025
Research perspectives for Europe
2 day international workshop for translational and clinical researchers,clinicians and epidemiologists to facilitate international research in Europe
If you have questions or comments for our study group, we warmly invite you to contact us!